Rona Therapeutics and Keymed Biosciences Partner to Unlock Potential of siRNA Therapeutics for Glomerulonephritis

Rona Therapeutics, Inc and Keymed Biosciences are teaming up to launch a groundbreaking collaboration to create the first-ever siRNA therapeutics for Glomerulonephritis, a severe kidney disease. Combining Rona’s RNAi targeting liver and extrahepatic tissues with Keymed’s scientific and technological expertise, the two companies are poised to revolutionize the way we treat this debilitating condition.

Rona and Keymed have joined forces to discover and identify siRNA lead compounds directed to a novel target related to glomerulonephritis. Leveraging Rona’s RAZOR™ platform, the two companies have partnered to develop and commercialize therapeutic product candidates, with the program expected to enter into clinical trials in the first half of 2024. Both companies will benefit from the collaboration with a profit/loss arrangement, and are looking forward to the exciting possibilities that may arise.

Rona is thrilled to join forces with Keymed in order to uncover and create innovative RNA medicinal products around the world. Our exclusive, cutting-edge siRNA platform technology, in combination with Keymed’s comprehensive knowledge in biology, will pave the way for the production of unparalleled siRNA treatments for diseases like glomerulonephritis. Together, we will revolutionize the medical industry and make a real difference in people’s lives.

Dr. Bo CHEN, the founder and CEO of Keymed, is delighted to announce the collaboration between Keymed and Rona, with a shared focus on addressing urgent unmet clinical needs and providing patients with high-quality, affordable, and innovative therapies.

Through the combination of Rona’s pioneering next generation siRNA platform and Keymed’s sophisticated biology expertise, this collaboration will open up exciting opportunities to explore potential targets that traditional therapeutic modalities have yet to successfully modulate.

Glomerulonephritis is a major cause of kidney damage, accounting for up to a third of all cases of end-stage renal disease. Common forms of primary glomerulonephritis include IgA Nephropathy, Lupus nephritis and Membranous nephropathy, which together affect millions of people around the world. Unfortunately, there are few approved drugs available to treat this serious condition, making the development of new medicines an urgent priority.

About Rona Therapeutics

Rona Therapeutics is revolutionizing the world of medicine with its groundbreaking RNA therapeutics platform. By developing modular and programmable RNA medicines, the company is dedicated to bringing innovative treatments to patients everywhere. With Rona, the future of medical science is here.

Rona is revolutionizing the field of RNA therapeutics with their cutting-edge RAZOR™ platform. Backed by blue-chip investors, Rona is pushing the boundaries of what is possible in the discovery of highly differentiated siRNA therapeutics.

With the help of their partners, they are aiming to bring these transformative treatments to patients suffering from metabolic syndrome, glomerulonephritis, CNS and ocular diseases.

About Keymed Biosciences

At Keymed Biosciences, we are leading the charge in the development of revolutionary biological therapies for autoimmune and oncological diseases. Our integrated platform allows us to swiftly uncover and develop treatments that can be advanced with remarkable speed and efficiency. Our diverse pipeline is a testament to our commitment to bringing life-changing treatments to those in need.

Leave a Comment